This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
The Sixth CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival will take place in autumn 2022 in New York City.
New York Academy of Sciences’ ninth annual convening of immuno-oncology experts across academia and industry sharing cutting-edge discoveries
Join CRI for an in-depth look into the newest and most exciting approach to vaccination in our lifetime… mRNA vaccines.
2020 International Cancer Immunotherapy Conference in New York City is canceled due to the COVID-19 pandemic.
The Symposium will bring together 15 accomplished faculty mentors to share their discoveries and research career experience in cancer immunology with 40 promising young scientists.
How science from the frontlines of immuno-oncology is helping inform strategies to treat and prevent COVID-19. Live stream event with Drs. Carl H. June, Miriam Merad, and E. John Wherry; moderated by Matthew Herper, STAT
The New York Academy of Sciences annual two-day meeting convenes top experts in tumor immunology, cancer genetics and computational biology.
The Fifth CRI-CIMT-EATI-AACR CICON takes place September 25-28, 2019, at Espace Grand Arche de la Défense in Paris, France.
Hosted by the Cancer Research Institute this intimate, invitation-only event for media and health care investment analysts will explore what’s next in the IO field.
This two-day symposium will convene leading experts in cancer immunotherapy to discuss cutting-edge findings in the broad area of combination therapies, including checkpoint inhibitors and cellular therapies.
CRI members receive a 20% off registration to the 5th annual Immuno-Oncology 360° in New York City.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.